CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 194 enrolled
Drug / intervention
PF-06650833 +3 moredrug
Likely dose
PF-06650833 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04092452
NCT04092452Phase 2Completed
CompareCT.gov

A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF-06650833, PF-06700841, AND PF-06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA

Pfizer·interventional·Posted Sep 17, 2019·Updated Jun 15, 2023

In Brief

A Phase 2 clinical trial evaluating PF-06650833, PF-06700841, and 2 other interventions for Acne Inversa. Completed, enrolled 194 participants across 77 sites in 3 countries.

Detailed Summary

This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week Follow up Period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Inversa
CountriesAustralia, Canada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 17, 2019
Enrollment StartDec 2, 2019
Primary CompletionJan 10, 2022
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 6.8 years ago

Interventions

PF-06650833drug

400 mg QD

PF-06700841drug

45 mg QD

PF-06826647drug

400 mg QD

Placebodrug

placebo